DRI Healthcare (TSE:DHT.UN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
DRI Healthcare Trust has expanded its portfolio by acquiring payment rights from Editas Medicine for the gene-edited cell therapy CASGEVY®, a treatment for sickle cell disease and beta thalassemia. The transaction ensures predictable annual cash flows for DRI, ranging from $5 million to $40 million, alongside potential sales-based milestones and a contingent payment until 2034. This strategic move not only diversifies DRI’s holdings but also supports the advancement of innovative rare disease therapies.
For further insights into TSE:DHT.UN stock, check out TipRanks’ Stock Analysis page.
